Clinical Case Reports (Aug 2021)

Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E

  • Donatello Salvatore,
  • Carmela Colangelo,
  • Michele D’Andria,
  • Giovanni Marsicovetere,
  • Domenica Passarella

DOI
https://doi.org/10.1002/ccr3.4713
Journal volume & issue
Vol. 9, no. 8
pp. n/a – n/a

Abstract

Read online

Abstract Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane regulator (CFTR) modulator. It is known to be efficacious in stable patients with severe pneumopathy, but there are few data concerning its effectiveness during acute exacerbations. We here describe its use in a woman with CF and respiratory failure.

Keywords